Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23871140 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23158203 | 0.88 | PPARA (0.46) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23143285 | 0.88 | PPARA (0.46) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23143284 | 0.88 | PPARA (0.46) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL24658508 | 0.84 | PPARA (0.45) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23871018 | 0.83 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL23870994 | 0.83 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL24884305 | 0.82 | PPARA (0.48) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23158209 | 0.80 | PPARA (0.47) | PPARAPPARGPPARDCYP1A1CYP1A2 | |
| SCHEMBL23158224 | 0.80 | PPARA (0.47) | PPARAPPARGPPARDCYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2023-01-12 | — | — | US | disclosed |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2022-11-17 | — | — | US | disclosed |
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | PPARA 94/4885PPARG 71/4885PPARD 332/4885 |
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | PPARA 94/4885PPARG 71/4885PPARD 332/4885 |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, CPT1A, CES1 | PPARA 27/4885PPARG 42/4885PPARD 144/4885 |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | PPARA 94/4885PPARG 71/4885PPARD 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.